Unknown

Dataset Information

A four-factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma.


ABSTRACT:

Background

Currently, the measurement of immune cells in previous studies is usually subjective, and no immune-based prognostic model has been established for chordoma. In this study, we sought to simultaneously measure tumor-infiltrating lymphocyte (TIL) subtypes in chordoma samples using an objective method and develop an immune risk score (IRS) model for survival prediction.

Methods

Multiplexed quantitative immunofluorescence staining was used to determine the TIL levels in the tumoral and stromal subareas of 114 spinal chordoma specimens (54 in the training and 60 in the validation cohort) for programmed death-1 (PD-1), CD3, CD8, CD20 (where CD is cluster of differentiation), and FOXP3. Flow cytometry was performed to validate the immunofluorescence assay for lymphocyte

SUBMITTER: Zou MX 

PROVIDER: S-EPMC7240847 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature